These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 16897589)

  • 1. Efficacy of voriconazole in experimental Cryptococcus neoformans infection.
    Mavrogiorgos N; Zaragoza O; Casadevall A; Nosanchuk JD
    Mycopathologia; 2006 Aug; 162(2):111-4. PubMed ID: 16897589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Voriconazole, combined with amphotericin B, in the treatment for pulmonary cryptococcosis caused by C. neoformans (serotype A) in mice with severe combined immunodeficiency (SCID).
    Silva EG; Paula CR; de Assis Baroni F; Gambale W
    Mycopathologia; 2012 Jun; 173(5-6):445-9. PubMed ID: 22071662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of fluconazole, voriconazole-resistant Cryptococcus neoformans isolated from and immunocompetent patient.
    Mandras N; Roana J; Tullio V; Allizond V; Banche G; Scalas D; Fucale G; Cuffini AM
    J Chemother; 2011 Dec; 23(6):379-80. PubMed ID: 22233828
    [No Abstract]   [Full Text] [Related]  

  • 4. Management of endogenous cryptococcal endophthalmitis with voriconazole.
    Vela JI; Díaz-Cascajosa J; Sanchez F; Roselló N; Buil JA
    Can J Ophthalmol; 2009 Dec; 44(6):e61-2. PubMed ID: 20051999
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of voriconazole in a murine model of cryptococcal central nervous system infection.
    Serena C; Pastor FJ; Mariné M; Rodríguez MM; Guarro J
    J Antimicrob Chemother; 2007 Jul; 60(1):162-5. PubMed ID: 17483143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro and in-vivo activities of SCH56592 against Cryptococcus neoformans.
    Hossain MA; Maesaki S; Mitsutake K; Kakeya H; Sasaki E; Tomono K; Tashiro T; Kohno S
    J Antimicrob Chemother; 1999 Dec; 44(6):827-9. PubMed ID: 10590286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sarcoid-like reaction in Cryptococcus neoformans infection.
    Yano S; Kobayashi K; Ikeda T; Kadowaki T; Wakabayashi K; Kimura M; Ishikawa S; Adachi Y; Araki K; Nagaoka S
    BMJ Case Rep; 2012 Jul; 2012():. PubMed ID: 22847562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifungal therapy in a murine model of disseminated infection by Cryptococcus gattii.
    Calvo E; Pastor FJ; Rodríguez MM; Pujol I; Guarro J
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4074-7. PubMed ID: 20625150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.
    Espinel-Ingroff A; Aller AI; Canton E; Castañón-Olivares LR; Chowdhary A; Cordoba S; Cuenca-Estrella M; Fothergill A; Fuller J; Govender N; Hagen F; Illnait-Zaragozi MT; Johnson E; Kidd S; Lass-Flörl C; Lockhart SR; Martins MA; Meis JF; Melhem MS; Ostrosky-Zeichner L; Pelaez T; Pfaller MA; Schell WA; St-Germain G; Trilles L; Turnidge J
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5898-906. PubMed ID: 22948877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination efficacy of voriconazole and amphotericin B in the experimental disease in immunodeficient mice caused by fluconazole-resistant Cryptococcus neoformans.
    Silva EG; Paula CR; Dias AL; Chang MR; Ruiz Lda S; Gambale V; Prates RA; Ribeiro MS
    Mycopathologia; 2011 Apr; 171(4):261-6. PubMed ID: 20972836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotypes of clinical cerebrospinal fluid Cryptococcus neoformans isolates from southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole.
    Chang WN; Huang CR; Lei CB; Lee PY; Chien CC; Chang HW; Chang CS; Lu CH
    Jpn J Infect Dis; 2004 Jun; 57(3):113-5. PubMed ID: 15218221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment with voriconazole combined with amphotericin B-liposome for fluconazole-resistant pulmonary cryptococcosis after renal transplantation.
    Fujioka K; Nagai T; Kinoshita Y; Urushihara M; Hamasaki Y; Shishido S; Kagami S
    CEN Case Rep; 2019 Nov; 8(4):261-265. PubMed ID: 31161376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulatory effect of voriconazole on the production of proinflammatory cytokines in experimental cryptococcosis in mice with severe combined immunodeficiency.
    Gonçalves Silva E; Marilia de Souza Silva S; Rodrigues Paula C; da Silva Ruiz L; Latercia Tranches Dias A
    J Mycol Med; 2018 Mar; 28(1):106-111. PubMed ID: 29273275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of azole resistance during fluconazole maintenance therapy for AIDS-associated cryptococcal disease.
    Friese G; Discher T; Füssle R; Schmalreck A; Lohmeyer J
    AIDS; 2001 Nov; 15(17):2344-5. PubMed ID: 11698718
    [No Abstract]   [Full Text] [Related]  

  • 15. New Triazole NT-a9 Has Potent Antifungal Efficacy against Cryptococcus neoformans
    Lu RY; Ni TJ; Wu J; Yan L; Lv QZ; Li LP; Zhang DZ; Jiang YY
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31791946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen.
    Nishikawa H; Fukuda Y; Mitsuyama J; Tashiro M; Tanaka A; Takazono T; Saijo T; Yamamoto K; Nakamura S; Imamura Y; Miyazaki T; Kakeya H; Yamamoto Y; Yanagihara K; Mukae H; Kohno S; Izumikawa K
    J Antimicrob Chemother; 2017 Jun; 72(6):1709-1713. PubMed ID: 28201509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a Cryptococcus neoformans cytochrome P450 lanosterol 14α-demethylase (Erg11) residue critical for differential susceptibility between fluconazole/voriconazole and itraconazole/posaconazole.
    Sionov E; Chang YC; Garraffo HM; Dolan MA; Ghannoum MA; Kwon-Chung KJ
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1162-9. PubMed ID: 22155829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model.
    Chandrasekar PH; Cutright J; Manavathu E
    J Antimicrob Chemother; 2000 May; 45(5):673-6. PubMed ID: 10797091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antifungal activity of D0870 against murine infections and its mechanism of action.
    Yamada H; Tsuda T; Watanabe T; Kusakabe S; Mochizuki H
    Chemotherapy; 1998; 44(2):112-20. PubMed ID: 9551242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of fluconazole (UK-49,858) against experimental aspergillosis and cryptococcosis in mice.
    Troke PF; Andrews RJ; Marriott MS; Richardson K
    J Antimicrob Chemother; 1987 May; 19(5):663-70. PubMed ID: 3038824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.